March 12th, 2014
Clinical Trials For Diabetes Drugs Need To Consider Heart Failure
Larry Husten, PHD
Is heart failure the missing 800 pound gorilla in diabetes trials? That’s the argument proposed by a group of prominent cardiovascular and diabetes researchers. It was long believed that by virtue of their glucose-lowering properties diabetes drugs would confer substantial cardiovascular benefits. That belief is no longer widely held, however, and the FDA now requires cardiovascular […]
October 7th, 2013
Selections from Richard Lehman’s Literature Review: October 7th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include several papers on the CV safety of diabetes drugs, a follow-up report from the WHI on hormone therapy, clopidogrel and smoking, and more.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?